TG Therapeutics TGTX Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about TG Therapeutics's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TG Therapeutics's total liabilities & equity?
- TG Therapeutics (TGTX) reported total liabilities & equity of $1.53B in Q1 2026.
- How has TG Therapeutics's total liabilities & equity changed year-over-year?
- TG Therapeutics's total liabilities & equity increased by 132.8% year-over-year, from $656.69M to $1.53B.
- What is the long-term trend for TG Therapeutics's total liabilities & equity?
- Over 5 years (2020 to 2025), TG Therapeutics's total liabilities & equity has grown at a 11.2% compound annual growth rate (CAGR), from $625.64M to $1.06B.
- What does total liabilities & equity mean?
- The total sum of all company debts and shareholder equity, which equals total assets.
- How do you interpret total liabilities & equity?
- Growth generally indicates the expansion of the company's asset base, whether funded by debt or equity.
- How does total liabilities & equity compare across companies?
- Used as a baseline for scaling other financial metrics to compare companies of different sizes.